Title: Biosimilar monoclonal antibodies
Authors: Declerck, Paul
Issue Date: 2015
Publisher: Future Science Group
Host Document: Bioanalysis for Biosimilars Development edition:e-book pages:Chapter-8
Article number: 8
Abstract: Monoclonal antibodies (MAs) are complex biotherapeutics as their molecular mechanism of action depends on multiple domains each contributing to the pharmacological and therapeutic properties of the molecule as well as to the safety profile. Consequently, biosimilar monoclonal antibodies constitute a unique class of biosimilars requiring specific guidelines for regulatory approval. An extensive comparative in vitro characterization to evaluate the biosimilarity of the various functional domains is required. Apart from typical protein analysis, evaluation of the glycosylation profile is of utmost importance. The exquisite species specificity of MAs precludes reliable in vivo nonclinical evaluations and means that adequately designed clinical studies are extremely critical to confirm the biosimilarity.
ISBN: 978-1-910419-33-5
Publication status: published
KU Leuven publication type: IHb
Appears in Collections:Therapeutic and Diagnostic Antibodies (+)

Files in This Item:
File Description Status SizeFormat
Biosimilar monoclonal antibodies_revised version_clean.pdfmanuscript Published 183KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.